This morning, we issued a Quarterly Update on AtheroNova Inc. (AHRO-OTC.BB), a development-stage biotech company creating novel compounds to dissolve or regress atherosclerotic plaque deposits. AtheroNova's most advanced product candidate, AHRO-001, works to significantly reduce the incidence and severity of plaque by employing a type of FDA-approved compound called a bile salt. In doing so, the Company seeks to address a +$37 billion market for lipid regulators--the drugs currently used to treat atherosclerosis and coronary artery disease. Atherosclerosis is a thickening of the arteries that occurs when fat, cholesterol, and other substances build up in the walls of the arteries and harden into plaque deposits. It is the primary cause of many cardiovascular diseases, including heart attack, stroke, and peripheral artery disease.

Partnership with OneMedPlace provides research and expanded media coverage to client companies

Biotech company AtheroNova Inc. (AHRO-OTC) this morning announced that it raised over $2.9 million in gross proceeds from a sale of its Common Stock. This funding represents a major milestone for the company, as it is expected to support both Phase I and Phase II clinical trials for AtheroNova's anti-atherosclerotic plaque compounds in development. AtheroNova's most advanced product candidate, AHRO-001, works to significantly reduce the incidence and severity of plaque deposits, which are known to be the main underlying cause of cardiovascular disease, including heart attack, stroke, and peripheral artery disease (PAD).

Crystal Research Associates' August 2012 nanotechnology update is now available here. This report is part of our ongoing coverage to our initial comprehensive industry review, Nanotechnology and the Built Environment: The Transition to Green Infrastructure, published November 2011 and available at www.crystalra.com.

EU Commission Finds Existing Regulatory Framework to be Sufficient for Governing Nanomaterials